| Literature DB >> 16895596 |
Francesca Porta1, Jukka Takala, Christian Weikert, Hendrik Bracht, Anna Kolarova, Bernhard H Lauterburg, Erika Borotto, Stephan M Jakob.
Abstract
INTRODUCTION: Sepsis may impair mitochondrial utilization of oxygen. Since hepatic dysfunction is a hallmark of sepsis, we hypothesized that the liver is more susceptible to mitochondrial dysfunction than the peripheral tissues, such as the skeletal muscle. We studied the effect of prolonged endotoxin infusion on liver, muscle and kidney mitochondrial respiration and on hepatosplanchnic oxygen transport and microcirculation in pigs.Entities:
Mesh:
Year: 2006 PMID: 16895596 PMCID: PMC1750984 DOI: 10.1186/cc5013
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Pulmonary artery pressure changes during the first 90 minutes of infusion. Pulmonary artery pressure (PAP) changes during the first 90 minutes of placebo infusion (filled circles) or during endotoxin infusion (open circles). *Friedman test, P < 0.001 group effect. Only the maximum PAP value (recorded manually) was included for one animal because part of the continually recorded data were lost due to a technical failure.
Summary of hemodynamic data of the endotoxin-infused and control groups
| Parameter | Group | Baseline | 1.5 hours | 3 hours | 6 hours | 12 hours | End of experiment |
| Heart rate (beats/minute) | Endotoxic | 115 (90–156) | 125.5 (97–139) | 132 (103–166) | 125 (96–157) | 117 (94–171) | 109 (98–181)b |
| Control | 101 (82–132) | 107 (87–141) | 111 (82–127) | 103 (78–136) | 100 (70–127) | 107 (80–117) | |
| Cardiac output (ml/kg/minute) | Endotoxic | 92 (61–146) | 93 (61–134) | 87 (42–143) | 102 (66–165) | 115 (58–149)a | 108 (74–152) |
| Control | 77 (60–143) | 86 (55–160) | 91 (53–142) | 91 (63–136) | 107 (70–147) | 103 (89–164) |
Data presented as the median (range). aFriedman test first 12 hours, P < 0.05. bMann–Whitney U test first 12 hours vs control, P < 0.05
Figure 2Mean arterial pressure changes over the course of the 24-hour experiment. Mean arterial pressure (MAP) changes in (a) the control group and (b) the endotoxin group. Dotted line, pig in which the biopsy samples were taken erroneously after 18 hours of the experiment. †P = 0.001 12 hours vs baseline; §P = 0.02 vs 12 hours.
Figure 3Mortality during the experiment.
Mitochondrial respiration and maximal ATP production in the muscle and the kidney at the end of the experiment
| Substrate | Group | Muscle | Kidney | ||
| Median (range) | Median (range) | ||||
| Glutamate | |||||
| State 3 | Endotoxic | 8 | 174 (93–114) | 7 | 93 (56–129) |
| Control | 9 | 223 (67–494) | 8 | 116 (49–165) | |
| State 4 | Endotoxic | 8 | 18 (13–42) | 7 | 22 (13–40) |
| Control | 9 | 20 (11–49) | 8 | 18 (11–27) | |
| Maximal ATP production | Endotoxic | 8 | 328 (187–940) | 7 | 184 (74–431) |
| Control | 9 | 606 (153–1233) | 8 | 221 (133–485) | |
| Respiratory control ratio | Endotoxic | 8 | 8.1 (6.7–11.8) | 7 | 4.0 (2.3–6.3) |
| Control | 9 | 8.3 (6.0–14.5) | 8 | 5.4 (3.7–7.1) | |
| Succinate | |||||
| State 3 | Endotoxic | 8 | 269 (167–467) | 7 | 194 (129–269) |
| Control | 9 | 307 (129–579) | 8 | 230 (107–269) | |
| State 4 | Endotoxic | 8 | 56 (36–82) | 7 | 67 (33–98) |
| Control | 9 | 62 (31–129) | 8 | 60 (36–78) | |
| Maximal ATP production | Endotoxic | 8 | 513 (356–944) | 7 | 460 (169–707) |
| Control | 9 | 611 (421–1164) | 8 | 469(193–1292) | |
| Respiratory control ratio | Endotoxic | 8 | 4.9 (2.9–7.0) | 7 | 3.3 (2.0–3.9) |
| Control | 9 | 4.1 (3.6–8.8) | 8 | 3.6 (3.0–3.9) | |
| Ascorbate/ | |||||
| State 3 | Endotoxic | 8 | 271 (189–401) | 7 | 134 (98–191) |
| Control | 9 | 316 (156–412) | 8 | 150 (116–401) | |
| State 4 | Endotoxic | 8 | 151 (100–200) | 7 | 91 (49–134) |
| Control | 9 | 147 (76–254) | 8 | 99 (62–169) | |
| Respiratory control ratio | Endotoxic | 8 | 1.9 (1.4–2.0) | 7 | 1.6 (1.4–2.7) |
| Control | 9 | 1.7 (1.4–2.9) | 8 | 1.8 (1.5–2.8) | |
Regional flows, microcirculation, and systemic and regional oxygen extraction and consumption
| Group | Baseline | 1.5 hours | 3 hours | 6 hours | 12 hours | End of experiment | |
| Renal blood flow (ml/kg/minute) | Endotoxic | 7.7 (2.3–10.5) | 7.3 (2.2–11.6) | 6.2 (2.4–9.5) | 6.1 (2.4–10.0) | 5.8 (2.7–10.8) | 3.9 (0.9–10.8)b |
| Control | 5.7 (1.9–9.5) | 5.6 (2.4–8.2) | 5.6 (2.9–7.6) | 6.0 (2.9–8.1) | 6.3 (3.0–7.9) | 5.1 (3.3–8) | |
| Total hepatic blood flow (ml/kg/minute) | Endotoxic | 23.2 (13.5–29.3) | 22.7 (16.7–27.6) | 25.5 (14–36.9) | 26.9 (23.3–31.6) | 26.7 (21.1–40)a | 24.5 (19.7–39.6) |
| Control | 21.5 (17.5–30) | 23.7 (17.5–25) | 24.8 (18.6–28) | 22.5 (21.3–28.1) | 26.1 (17.5–29) | 25.3 (23.5–42.3) | |
| Liver blood perfusion units (%) | Endotoxic | 100 | 104 (58–229) | 111 (48–212) | 97 (51–238) | 86 (27–212) | 70 (22–194) |
| Control | 100 | 112 (62–156) | 122 (53–221) | 94 (43–282) | 94 (65–376) | 93 (27–251) | |
| Renal blood perfusion units (%) | Endotoxic | 100 | 101 (28–170) | 100 (37–141) | 89 (31–151) | 93 (42–132) | 45 (27–102)b |
| Control | 100 | 71 (35–200) | 93 (32–157) | 62 (22–171) | 90 (20–617) | 55 (16–660) | |
| Systemic VO2 (ml/kg/minute) | Endotoxic | 6.5 (4.7–11.7) | 7.1 (3.8–10.7) | 7.7 (4.2–11.1) | 7 (5.3–10.1) | 7.8 (4.9–8.9) | 6.9 (4.6–9.3) |
| Control | 5.2 (4.5–8.4) | 6.4 (3.9–7.9) | 7.1 (3.2–8.1) | 6.1 (3.6–8.9) | 7.0 (3.9–8.2) | 6.0 (3.8–8.1) | |
| Hepatic VO2 (ml/kg/minute) | Endotoxic | 0.9 (0.3–1.5) | 1.0 (0.5–1.5) | 1.1 (0.5–2.6) | 1.3 (0.7–2.1) | 1.1 (0.6–1.8) | 1.1 (0.4–1.8) |
| Control | 1.0 (0.8–2.0) | 1.0 (0.9–1.2) | 1.0 (0.7–1.2) | 1.1 (0.9–1.5) | 1.1 (0.8–1.4) | 1.1 (0.7–1.7) | |
| Renal VO2 (ml/kg/minute) | Endotoxic | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 0.3 (0.1–0.3) | 0.2 (0.04–0.3) |
| Control | 0.2 (0.1–0.3) | 0.2 (0.1–0.2) | 0.2 (0.1–0.2) | 0.2 (0.2–0.2) | 0.2 (0.2–0.3) | 0.2 (0.1–0.3) | |
| Systemic oxygen extraction (%) | Endotoxic | 57 (43–71) | 56 (41–74) | 63 (39–73) | 62 (47–70) | 55 (42–66) | 60 (50–88) |
| Control | 57 (37–65) | 56 (45–66) | 59 (43–69) | 57 (38–70) | 54 (39–63) | 50 (30–70) | |
| Hepatic oxygen extraction (%) | Endotoxic | 46 (35–82) | 49 (21–78) | 57 (27–84) | 60 (33–74) | 54 (34–66) | 61 (30–74) |
| Control | 60 (53–73) | 62 (39–70) | 58 (29–74) | 56 (45–78) | 61 (34–72) | 53 (30–75) | |
| Renal oxygen extraction (%) | Endotoxic | 24 (17–37) | 21 (18–41) | 24 (20–30) | 26 (25–53) | 29 (21–42)a | 36 (28–82)b |
| Control | 25 (17–60) | 22 (15–55) | 24 (17–52) | 26 (19–54) | 24 (21–58) | 30 (24–52) |
Data presented as the median (range). aFriedman test first 12 hours, P < 0.01. bWilcoxon test, P < 0.05 vs 12 hours.
Arterial lactate; systemic and regional lactate/pyruvate ratios; regional lactate exchange
| Group | Baseline | 1.5 hours | 3 hours | 6 hours | 12 hours | End of experiment | |
| Arterial lactate (mmol/l) | Endotoxic | 0.8 (0.4–1.2) | 1.0 (0.5–1.3) | 0.9 (0.7–1.7) | 0.9 (0.7–1.1) | 0.8 (0.5–1.0) | 0.9 (0.6–4.2) |
| Control | 0.9 (0.7–1.2) | 0.7 (0.5–1.2) | 0.7 (0.5–1) | 0.7 (0.5–1.0) | 0.5 (0.4–0.8) | 0.5 (0.3–1.1) | |
| Systemic lactate/pyruvate ratio | Endotoxic | 9.4 (6.7–17.0) | 9.5 (7.1–18.3) | 11.0 (6.7–23.7) | 8.9 (7.5–14.1) | 9.5 (6.6–10.4) | 11.9 (8.5–27.1)a |
| Control | 9.5 (5.7–13.6) | 8.1 (5.4–10.0) | 8.7 (7.1–10.9) | 8.7 (7.2–11.3) | 8.5 (5.4–11.8) | 7.3 (5.6–11.6) | |
| Hepatic lactate/pyruvate ratio | Endotoxic | 9.7 (7.3–27.6) | 10.3 (5.7–19.8) | 10.7 (6.9–18.6) | 9.4 (6.2–18.1) | 7.9 (6.2–16.7) | 12.1 (7.5–33.0) |
| Control | 12.4 (3.9–46.9) | 9.2 (4.5–26.7) | 9.9 (6.7–34.9) | 8.2 (5.4–28.3) | 7.0 (4.9–30.8) | 9.2 (5.8–25.3) | |
| Renal lactate/pyruvate ratio | Endotoxic | 8.0 (6.0–10.0) | 8.4 (5.5–35.9) | 9.8 (6.6–12.5) | 8.0 (5.4–15.7) | 7.4 (6.3–9.8) | 8.1 (7.3–33.6) |
| Control | 8.7 (6.5–11.0) | 7.9 (5.7–13.1) | 8.6 (6.1–14.4) | 8.7 (5.2–36.1) | 7.3 (5.8–37.3) | 8.7 (5.3–14.2) | |
| Renal lactate exchange (μmol/minute) | Endotoxic | 1.4 (–1.5–2.1) | 1.0 (–12.1–1.6) | 0.9 (–3.2–2.4) | 0.6 (–0.9–1.2) | 0.8 (–0.7–2.6) | 1.1 (–7.8–2.4) |
| Control | 0.7 (–3.5–1.6) | 0.1 (–4.5–1.5) | 0.3 (–1.7–1.3) | 0.6 (–11.1–1.3) | 0.5 (–9.9–1.5) | 0.3 (–1.5–1.4) | |
| Hepatic lactate exchange (μmol/kg/minute) | Endotoxic | 9.0 (5.2–20.1) | 8.7 (–11.0–22.4) | 9.7 (7.4–21.3) | 11.6 (9.6–19.0) | 12.7 (6.5–18.6) | 10.8 (–17.5–15.2) |
| Control | 10.3 (0.8–18.2) | 9.0 (5.9–15.0) | 8.6 (3.8–19.0) | 7.3 (4.7–16.9) | 9.2 (3.5–16.7) | 9.4 (5.2–16.7) |
Data presented as the median (range).
Figure 4Glutamate-dependent respiration rates, respiratory control ratio and ADP added/oxygen consumed ratios in the liver. Glutamate-dependent state 3 and state 4 respiration rates (nanoatom/min/mg protein), the respiratory control ratio (RCR) and the ADP added/oxygen consumed (ADP:O) ratio (nanomol/nanoatom) in liver biopsies after placebo infusion (filled circles) and after endotoxin infusion (open circles). *P = 0.002 vs control group; †P = 0.000 vs control group, §P = 0.014 vs control group.
Figure 5Succinate-dependent respiration rates, respiratory control ratio and ADP added/oxygen consumed ratios in the liver. Succinate-dependent state 3 and state 4 respiration rates (nanoatom/min/mg protein), the respiratory control ratio (RCR) and the ADP added/oxygen consumed (ADP:O) ratio (nanomol/nanoatom) in liver biopsies after placebo infusion (filled circles) and after endotoxin infusion (open circles). *P = 0.001 vs control group; †P = 0.003 vs control group; §P = 0.001 vs control group.